(Total Views: 277)
Posted On: 05/04/2017 8:26:24 AM
Post# of 22801
$MDXG,,,Just looked at chart,,,nothing but up,,,shows below that company maybe overvalued but share price continues to soar as they reported a really good earnings estimate a few days ago. I plan to keep my peepers on this one.
MiMedx Group, Inc.: Leads amongst peers with strong fundamentals
May 1, 2017 by CapitalCube
MiMedx Group, Inc. relative valuation is OVERVALUED and it has a fundamental analysis score of 78.
Our analysis is based on comparing MiMedx Group, Inc. with the following peers – Teleflex Incorporated, Medtronic plc, Hill-Rom Holdings, Inc., Sonoma Pharmaceuticals, Inc., CryoLife, Inc., NuVasive, Inc., STERIS Plc, Alphatec Holdings, Inc. and C. R. Bard, Inc. (TFX-US, MDT-US, HRC-US, SNOA-US, CRY-US, NUVA-US, STE-US, ATEC-US and BCR-US).
MiMedx Group, Inc. has shown good performance overall, both over the last one year (at 62.69%) as well as over the last month (at 30.82%). Share price performance over the last month, though has been lower than that over the last year. But MiMedx Group, Inc.’s stock has done better than its overall peer group whose performance was 6.83% over the last month.
Company Snapshot
Considering peers, relative outperformance over the last year and the last month suggest a leading position.
It currently trades at a Price/Book ratio of (10.90).
MDXG-US outperforms its peers with a relatively high operating performance and the market also expects faster growth relative to its peers
MDXG-US‘s median net profit margins and relatively high asset efficiency give it some operating leverage.
Changes in annual revenues (relative to peers) are better than the change in its earnings (relative to peers), implying the company is focused more on revenues.
Over the last five years, MDXG-US‘s return on assets has improved from below median to better than the median among its peers, suggesting that the company has improved its relative operations markedly.
The company’s relatively high gross margin suggests some differentiation with pricing advantages versus peers.
Compared with the peers chosen, MDXG-US has had faster revenue growth in prior years and a current P/E ratio that suggests faster growth in the future suggesting superior growth expectations.
The company’s level of capital investment suggests it might be under-investing in a business with above median returns.
MDXG-US has the financial and operating capacity to borrow quickly.
Our analysis rates MiMedx Group, Inc. as OVERVALUED relative to its peers.
Share Price Performance
Considering peers, relative outperformance over the last year and the last month suggest a leading position.
MDXG-US‘s share price performance of 62.69% over the last 12 months is above peer median of 36.08%. The 30-day trend in its share price performance of 30.82% is also above the peer median of 6.83% suggesting that this company is a leading performer relative to its peers.
Share Price Performance
Quadrant label definitions. Hover to know more
Leading, Fading, Lagging, Rising
Relative Valuation
MiMedx Group, Inc.: Leads amongst peers with strong fundamentals
May 1, 2017 by CapitalCube
MiMedx Group, Inc. relative valuation is OVERVALUED and it has a fundamental analysis score of 78.
Our analysis is based on comparing MiMedx Group, Inc. with the following peers – Teleflex Incorporated, Medtronic plc, Hill-Rom Holdings, Inc., Sonoma Pharmaceuticals, Inc., CryoLife, Inc., NuVasive, Inc., STERIS Plc, Alphatec Holdings, Inc. and C. R. Bard, Inc. (TFX-US, MDT-US, HRC-US, SNOA-US, CRY-US, NUVA-US, STE-US, ATEC-US and BCR-US).
MiMedx Group, Inc. has shown good performance overall, both over the last one year (at 62.69%) as well as over the last month (at 30.82%). Share price performance over the last month, though has been lower than that over the last year. But MiMedx Group, Inc.’s stock has done better than its overall peer group whose performance was 6.83% over the last month.
Company Snapshot
Considering peers, relative outperformance over the last year and the last month suggest a leading position.
It currently trades at a Price/Book ratio of (10.90).
MDXG-US outperforms its peers with a relatively high operating performance and the market also expects faster growth relative to its peers
MDXG-US‘s median net profit margins and relatively high asset efficiency give it some operating leverage.
Changes in annual revenues (relative to peers) are better than the change in its earnings (relative to peers), implying the company is focused more on revenues.
Over the last five years, MDXG-US‘s return on assets has improved from below median to better than the median among its peers, suggesting that the company has improved its relative operations markedly.
The company’s relatively high gross margin suggests some differentiation with pricing advantages versus peers.
Compared with the peers chosen, MDXG-US has had faster revenue growth in prior years and a current P/E ratio that suggests faster growth in the future suggesting superior growth expectations.
The company’s level of capital investment suggests it might be under-investing in a business with above median returns.
MDXG-US has the financial and operating capacity to borrow quickly.
Our analysis rates MiMedx Group, Inc. as OVERVALUED relative to its peers.
Share Price Performance
Considering peers, relative outperformance over the last year and the last month suggest a leading position.
MDXG-US‘s share price performance of 62.69% over the last 12 months is above peer median of 36.08%. The 30-day trend in its share price performance of 30.82% is also above the peer median of 6.83% suggesting that this company is a leading performer relative to its peers.
Share Price Performance
Quadrant label definitions. Hover to know more
Leading, Fading, Lagging, Rising
Relative Valuation
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼
